MindMaze Therapeutics Holding SA (SIX: MMTX) announced the results of its Annual General Meeting held earlier today. Shareholders approved all proposals submitted by the Board of Directors, except the proposed increase in conditional share capital, which did not obtain the required qualified majority.
Shareholders re-elected Walid Hanna, Olaf Blanke and Martin Reiss to the Board of Directors and elected Brad Hollinger, Founder, Chairman and Chief Executive Officer of Vibra Healthcare, and Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, as new members of the Board of Directors. These additions bring fresh perspectives from the healthcare and executive leadership sectors, which could enhance the company's strategic direction in precision neurotherapeutics.
In addition, shareholders approved the 2025 Annual Report and financial statements, the appropriation of available earnings, the discharge of the members of the Board of Directors and the Executive Committee, the re-election of Walid Hanna as Chairman of the Board of Directors, the elections to the Nomination and Compensation Committee, the re-election of the Independent Proxy and the statutory auditor, the compensation proposals for the Board of Directors and Executive Committee, and the consultative vote on the 2025 Compensation Report.
Further information on the proposals submitted to shareholders is available in the AGM Invitation. Detailed voting results will be published on the Company’s website later today.
MindMaze Therapeutics is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company’s FDA-cleared and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other neurological disorders. With an extensive library of rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.
The outcome of the AGM is significant as it confirms shareholder support for the company's governance and strategic direction, despite the rejection of the conditional capital increase. This decision could impact the company's future financing flexibility. The election of new board members with deep industry experience may strengthen the company's ability to execute its growth plans in the neurotherapeutics market. For more information, visit www.mindmazetherapeutics.com.
